PFE · Company research
Pfizer Inc. (PFE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
80records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth | GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0.111 | 1 |
| Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It | Pfizer has been trending on Zacks.com with shares returning +6.1% over the past month, outperforming the S&P 500's +0.7% gain. However, the company faces headwinds with earnings expected to decline 8.4% year-over-year for the current fiscal year and revenue projected to remain flat. Despite beating consensus estimates in recent quarters and trading at a discount to peers, Pfizer received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0 | 1 |
| Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? | Pfizer stock has gained 18% this year amid a potential rotation from tech to healthcare stocks. The company offers an attractive 5.8% dividend yield and trades at a forward P/E multiple of around 10, suggesting significant undervaluation despite a high trailing P/E of 37 due to restructuring charges. Analysts believe the stock has substantial upside potential as the market recognizes its value. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 1 | 1 |
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch | Pfizer will report Q3 2026 earnings on November 3, with focus on non-oncology segments. Eliquis demand is expected to boost Primary Care sales, while COVID-19 vaccine and Paxlovid revenues will decline. Specialty Care segment may see Vyndaqel growth offset by declines in Xeljanz and Enbrel due to competitive pressures. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.167 | 1 |
| Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? | Corcept Therapeutics reported Korlym sales of $373.5 million in H1 2026, up 6.2% year-over-year. The FDA approval of Lifyorli (relacorilant) in March 2026 generated $47.6 million in Q2 2026, marking the company's first quarter of commercial availability. The new drug aims to reduce CORT's dependence on Korlym. Relacorilant is also being studied in combination with other therapies for various cancers, with an FDA decision on the Cushing's syndrome indication expected by December 2026. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now? | SPHD is a smart beta ETF launched in 2012 with $3.29 billion in assets, offering exposure to 50 S&P 500 stocks with high dividend yields and low volatility. With a 0.30% expense ratio, 4.87% dividend yield, and year-to-date performance of 9.36%, it presents a reasonable option for value investors, though cheaper alternatives like SCHD and VTV exist with significantly larger asset bases. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| PFE Stock Gains 0.48%, Testing Key: Explained - JournalArta | PFE Stock Gains 0.48%, Testing Key: Explained JournalArta | View source ↗ | JournalArta | Oct 19, 2026 | neutral | 0 | 0.6 |
| Pfizer (PFE) Stock Looks Richly Priced On Current Earnings - Simply Wall Street | Pfizer (PFE) Stock Looks Richly Priced On Current Earnings Simply Wall Street | View source ↗ | Simply Wall Street | Oct 18, 2026 | neutral | 0 | 0.6 |
| Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? | BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors. | View source ↗ | The Motley Fool | Oct 18, 2026 | neutral | 0 | 1 |
| Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year | The article examines five high-yield dividend stocks with yields ranging from 5.88% to 16.72%. Featured stocks include Altria Group (5.93% yield, 57-year dividend streak), AGNC Investment (16.72% yield but at risk from rising rates), Energy Transfer (6.57% yield, 19 consecutive quarters of increases), Pfizer (6.06% yield, 352 consecutive quarterly dividends), and Realty Income (5.88% yield, 116 consecutive quarters of increases). While these stocks offer steady income, investors should be aware of sector-specific risks including interest rate sensitivity and commercial real estate headwinds. | View source ↗ | The Motley Fool | Oct 18, 2026 | bullish | 0.273 | 1 |
| Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline | BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.2 | 1 |
| Pfizer Inc. (PFE) Stock Price, News, Quote & History - Yahoo! Finance Canada | Pfizer Inc. (PFE) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.167 | 1 |
| Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends | AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer. | View source ↗ | The Motley Fool | Oct 16, 2026 | neutral | 0 | 1 |
| Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? | Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 1 | 1 |
| Johnson & Johnson: 3 Key Takeaways for Long-Term Investors | Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Johnson & Johnson: 3 Key Takeaways for Long-Term Investors | Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Why Did PFE, MMED, DE Stocks Surge To 52-Week Highs Today? - Stocktwits | Why Did PFE, MMED, DE Stocks Surge To 52-Week Highs Today? Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| 6 Blue Chip Stocks Trading Well Below Their Highs | Six major blue-chip stocks—Nike, Goldman Sachs, Intel, Disney, Pfizer, and Home Depot—are trading at least 20% below their all-time highs despite a strong bull market. The article analyzes each stock to determine whether they represent bargains or value traps, considering factors like valuation metrics, competitive pressures, and market sentiment. | View source ↗ | The Motley Fool | Oct 16, 2026 | neutral | 0 | 1 |
| 6 Blue Chip Stocks Trading Well Below Their Highs | Six major blue-chip stocks—Nike, Goldman Sachs, Intel, Disney, Pfizer, and Home Depot—are trading at least 20% below their all-time highs despite a strong bull market. The article analyzes each stock to determine whether they represent bargains or value traps, considering factors like valuation metrics, competitive pressures, and market sentiment. | View source ↗ | The Motley Fool | Oct 16, 2026 | neutral | 0 | 1 |
| Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE) - Yahoo Finance | Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE) Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win - Stocktwits | PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| 2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends | Verizon Communications and Pfizer are highlighted as attractive high-yield dividend stocks for income investors. Verizon offers a 6.5% forward dividend yield backed by strong subscriber growth and improved customer retention, while Pfizer provides a 6.1% yield with a 352-consecutive-quarter dividend history and growth potential from its oncology pipeline and 96 research programs. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 1 | 1 |
| 2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends | Verizon Communications and Pfizer are highlighted as attractive high-yield dividend stocks for income investors. Verizon offers a 6.5% forward dividend yield backed by strong subscriber growth and improved customer retention, while Pfizer provides a 6.1% yield with a 352-consecutive-quarter dividend history and growth potential from its oncology pipeline and 96 research programs. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 1 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Pfizer Stock Hits 52-Week High: What's Going On? - Benzinga | Pfizer Stock Hits 52-Week High: What's Going On? Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| Pfizer (PFE) Could Be 60% Below Fair Value On Tukysa Approval And Vaccine Data - Simply Wall Street | Pfizer (PFE) Could Be 60% Below Fair Value On Tukysa Approval And Vaccine Data Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today? - TradingView | Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today? TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| Pfizer (PFE) Gains As Market Dips: What You Should Know | Pfizer (PFE) closed at $29.21, up 2.96% on the day, outperforming the S&P 500. However, the company faces headwinds with projected Q3 EPS declining 17.24% year-over-year and full-year earnings expected to drop 8.39%. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 9.63, trading at a discount to industry averages. Earnings are scheduled for November 3, 2026. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Pfizer will present the first RSV vaccine data from nursing homes after three seasons - Stock Titan | Pfizer will present the first RSV vaccine data from nursing homes after three seasons Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Pfizer: The Earnings Test That Matters (NYSE:PFE) - Seeking Alpha | Pfizer: The Earnings Test That Matters (NYSE:PFE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| PFE Stock Gains 0.42%, Testing Key: Explained - JournalArta | PFE Stock Gains 0.42%, Testing Key: Explained JournalArta | View source ↗ | JournalArta | Oct 13, 2026 | neutral | 0 | 0.6 |
| BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? | Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential. However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0 | 1 |
| How to Play PFE Stock as Pfizer Cuts 300 Jobs - Barchart.com | How to Play PFE Stock as Pfizer Cuts 300 Jobs Barchart.com | View source ↗ | Barchart.com | Oct 12, 2026 | neutral | 0 | 0.6 |
| Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - TradingView | Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? TradingView | View source ↗ | TradingView | Oct 12, 2026 | neutral | 0 | 0.6 |
| Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? | Pfizer's stock has moved above its 50-day moving average, supported by new drug launches and acquisitions. While the company faces significant headwinds from declining COVID-19 product sales and an upcoming patent cliff, its diversified portfolio, strong oncology pipeline, obesity drug berobenatide program, attractive 6.1% dividend yield, and $9.7 billion in cost savings through 2029 provide support. Analysts recommend holding the stock at current levels given its inexpensive valuation relative to peers. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.667 | 1 |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how to identify stocks with positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter, which compares the most recent analyst estimates against consensus estimates. The strategy combining positive ESP with Zacks Rank #3 or better has historically resulted in 70% positive earnings surprises and 28.3% average annual returns. Johnson & Johnson and Pfizer are highlighted as medical stocks with positive ESPs ahead of their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| Is Pfizer (PFE) Overvalued Even After Its Oncology Progress? - Yahoo Finance | Is Pfizer (PFE) Overvalued Even After Its Oncology Progress? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Top Research Reports for JPMorgan, ASML & Chevron | Zacks Research Daily features analysis of 16 major stocks including JPMorgan Chase, ASML, and Chevron, plus two microcap stocks. JPMorgan benefits from strong earnings and diversified revenues; ASML faces balanced opportunities and risks from AI demand; Chevron shows strong production growth and cash flow. Additional coverage includes Pfizer, Valero Energy, and Constellation Energy, with mixed outlooks across sectors. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Roche Gets FDA Approval for Another Label Expansion of Tecentriq | Roche received FDA approval for Tecentriq in combination with chemotherapy for adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The phase III ATOMIC study demonstrated a 50% reduction in recurrence or death risk, with 86% disease-free survival at 36 months versus 76% for chemotherapy alone. This marks Tecentriq's 12th U.S. indication and positions it as the first approved adjuvant immunotherapy for this cancer type. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Roche Gets FDA Approval for Another Label Expansion of Tecentriq | Roche received FDA approval for Tecentriq in combination with chemotherapy for adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The phase III ATOMIC study demonstrated a 50% reduction in recurrence or death risk, with 86% disease-free survival at 36 months versus 76% for chemotherapy alone. This marks Tecentriq's 12th U.S. indication and positions it as the first approved adjuvant immunotherapy for this cancer type. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know | Pfizer has been heavily searched on Zacks.com lately. The stock returned +0.6% over the past month, underperforming the S&P 500's +1.3% gain. Pfizer holds a Zacks Rank #2 (Buy) rating based on earnings estimate revisions and other factors. The company is expected to report declining earnings year-over-year but has consistently beaten consensus estimates in recent quarters. Pfizer trades at a valuation discount to peers with a B grade on the Value Style Score. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know | Pfizer has been heavily searched on Zacks.com lately. The stock returned +0.6% over the past month, underperforming the S&P 500's +1.3% gain. Pfizer holds a Zacks Rank #2 (Buy) rating based on earnings estimate revisions and other factors. The company is expected to report declining earnings year-over-year but has consistently beaten consensus estimates in recent quarters. Pfizer trades at a valuation discount to peers with a B grade on the Value Style Score. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance | Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Pfizer (PFE) Stock Looks Expensive Following Its 18% One Year Gain - Simply Wall Street | Pfizer (PFE) Stock Looks Expensive Following Its 18% One Year Gain Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth | The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth | The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug - Stocktwits | PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Should You Be Worried About Pfizer Stock? - Trefis | Should You Be Worried About Pfizer Stock? Trefis | View source ↗ | Trefis | Oct 9, 2026 | neutral | 0 | 0.6 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? | Pfizer (PFE) is highlighted as a stock well-positioned to continue beating earnings estimates in its upcoming report on November 3, 2026. The company has surpassed consensus estimates by an average of 9.43% in the last two quarters and currently has a positive Earnings ESP of +12.30% combined with a Zacks Rank #2 (Buy) rating, suggesting a high probability of another earnings beat. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? | Pfizer (PFE) is highlighted as a stock well-positioned to continue beating earnings estimates in its upcoming report on November 3, 2026. The company has surpassed consensus estimates by an average of 9.43% in the last two quarters and currently has a positive Earnings ESP of +12.30% combined with a Zacks Rank #2 (Buy) rating, suggesting a high probability of another earnings beat. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? | Pfizer (PFE) is highlighted as a stock well-positioned to continue beating earnings estimates in its upcoming report on November 3, 2026. The company has surpassed consensus estimates by an average of 9.43% in the last two quarters and currently has a positive Earnings ESP of +12.30% combined with a Zacks Rank #2 (Buy) rating, suggesting a high probability of another earnings beat. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer | Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) figures that could beat their upcoming earnings estimates. Pfizer (PFE) has a +12.30% ESP with a #2 Buy rating ahead of its November 3, 2026 earnings release, while Johnson & Johnson (JNJ) has a +2.10% ESP with a #3 Hold rating before reporting on October 13, 2026. Both stocks are positioned to potentially outperform analyst expectations. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) figures that could beat their upcoming earnings estimates. Pfizer (PFE) has a +12.30% ESP with a #2 Buy rating ahead of its November 3, 2026 earnings release, while Johnson & Johnson (JNJ) has a +2.10% ESP with a #3 Hold rating before reporting on October 13, 2026. Both stocks are positioned to potentially outperform analyst expectations. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.